CYTEK BIOSCIENCES, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-66.5M | $-6.0M | $-12.1M | $2.5M | $3.0M | $19.4M |
| Depreciation & Amortization | $7.6M | $7.2M | $6.0M | $2.5M | $1.2M | $603.0K |
| Depreciation | $3.9M | $3.5M | $2.8M | $1.7M | $900.0K | $500.0K |
| Amortization | $3.7M | $3.7M | $3.2M | $800.0K | $300.0K | $71.0K |
| Stock-Based Compensation | $24.6M | $26.8M | $22.0M | $16.6M | $6.6M | $611.0K |
| Net Cash from Operating Activities | $-4.7M | $25.4M | $5.3M | $-12.2M | $4.6M | $15.2M |
| Investing Activities | ||||||
| Capital Expenditures | $4.1M | $3.5M | $4.6M | $9.7M | $4.4M | $1.5M |
| Business Acquisitions | $0 | $471.0K | $44.9M | $0 | $17.0M | $0 |
| Net Cash from Investing Activities | $10.1M | $-83.0M | $-93.9M | $-55.9M | $-21.0M | $-1.5M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | $15.1M | $21.6M | $44.2M | $0 | $0 | — |
| Net Cash from Financing Activities | $-13.4M | $-15.8M | $-41.8M | $5.5M | $213.6M | $122.6M |
| Net Change in Cash | $-7.9M | $-68.9M | $-131.9M | $-65.1M | $198.5M | $135.6M |
| Free Cash Flow | $-8.8M | $21.9M | $633.0K | $-22.0M | $266.0K | $13.6M |